BHVN

Biohaven (BHVN)

Biohaven Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:BHVN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/29	20:30	PR Newswire (US)	Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day	NYSE:BHVN	Biohaven Ltd
2024/05/29	20:15	PR Newswire (US)	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	NYSE:BHVN	Biohaven Ltd
2024/05/18	05:42	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2024/05/18	05:41	Edgar (US Regulatory)	Form 424B7 - Prospectus [Rule 424(b)(7)]	NYSE:BHVN	Biohaven Ltd
2024/05/10	05:16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NYSE:BHVN	Biohaven Ltd
2024/05/10	05:14	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2024/05/10	05:05	PR Newswire (US)	Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
2024/04/23	05:05	PR Newswire (US)	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares	NYSE:BHVN	Biohaven Ltd
2024/04/18	05:05	PR Newswire (US)	Biohaven Announces Proposed Public Offering of Common Shares	NYSE:BHVN	Biohaven Ltd
2024/04/13	22:00	PR Newswire (US)	Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates	NYSE:BHVN	Biohaven Ltd
2024/03/01	06:16	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2024/03/01	06:05	PR Newswire (US)	Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
2024/01/08	21:30	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2024/01/08	21:30	PR Newswire (US)	Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo	NYSE:BHVN	Biohaven Ltd
2024/01/02	21:00	PR Newswire (US)	Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NYSE:BHVN	Biohaven Ltd
2023/12/02	06:30	PR Newswire (US)	Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting	NYSE:BHVN	Biohaven Ltd
2023/11/15	06:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:BHVN	Biohaven Ltd
2023/11/15	06:05	PR Newswire (US)	Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
2023/10/16	20:00	PR Newswire (US)	Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®	NYSE:BHVN	Biohaven Ltd
2023/10/06	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2023/10/06	05:05	PR Newswire (US)	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares	NYSE:BHVN	Biohaven Ltd
2023/10/05	05:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:BHVN	Biohaven Ltd
2023/10/03	12:56	PR Newswire (US)	Biohaven Announces Pricing of $225 Million Public Offering of Common Shares	NYSE:BHVN	Biohaven Ltd
2023/10/03	10:41	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2023/10/03	06:09	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:BHVN	Biohaven Ltd
2023/10/03	06:07	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:BHVN	Biohaven Ltd
2023/10/03	05:36	PR Newswire (US)	BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES	NYSE:BHVN	Biohaven Ltd
2023/10/03	05:01	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NYSE:BHVN	Biohaven Ltd
2023/09/27	19:58	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
2023/09/14	20:00	PR Newswire (US)	Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy	NYSE:BHVN	Biohaven Ltd